Related Experiment Video
Updated: Jun 28, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial
Zachary A Kopelman1, Chunqiao Tian2, Jordyn Tumas1
1Gynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD, USA; Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Black patients with endometrioid endometrial carcinoma (EEC) face worse outcomes and distinct molecular profiles compared to White patients. Addressing these racial disparities requires targeted therapies and inclusive clinical trials.
Area of Science:
- Oncology
- Genetics
- Health Disparities
Background:
- Endometrioid endometrial carcinoma (EEC) disproportionately affects Black women, with existing data suggesting poorer outcomes.
- Understanding the molecular underpinnings and clinical presentation differences is crucial for addressing racial disparities in EEC.
Purpose of the Study:
- To investigate racial disparities in clinical outcomes and molecular features between Black and White patients diagnosed with EEC.
- To compare survival rates, disease characteristics, and genetic mutations in EEC patients across different racial groups.
Main Methods:
- Retrospective analysis of large patient cohorts from SEER, NCDB, GENIE, and NCI-sponsored randomized phase III clinical trials (RCTs).
- Utilized hazard ratios (HR) and propensity-score matching to compare cancer-related death (CRD), non-cancer death (NCD), and all-cause death between Black and White EEC patients.
- Analyzed mutation frequencies of key genes (e.g., PTEN, TP53) and tumor mutational burden (TMB) in relation to race.
Main Results:
- Black patients exhibited significantly higher risks of CRD and NCD compared to White patients in SEER and NCDB datasets.
- After propensity-score matching, Black patients still showed an increased risk of death, particularly in real-world data.
- Molecular analysis revealed fewer PI3K-pathway-related mutations but similar TP53 and DNA-repair gene mutation frequencies in Black patients.
- In RCTs, Black patients presented with more advanced disease, higher grade, and worse performance status, correlating with increased mortality risk.
Conclusions:
- Significant racial disparities exist in clinical presentation, outcomes, and molecular profiles for patients with EEC.
- Strategies including targeted drug development, addressing social determinants of health, and increasing diversity in clinical trials are essential to mitigate these disparities.
More Related Videos
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Survival Analysis
Comparing the Survival Analysis of Two or More Groups